<a href="https://laohu8.com/S/FTFI">First Berlin</a> Equity Research Raises <a href="https://laohu8.com/S/INRLF">Valneva SE</a> Price Target to €6.80
First Berlin Equity Research has published an update on Valneva SE, maintaining a "Buy" recommendation and raising the 12-month price target from €6.30 to €6.80. Analyst Simon Scholes cited the advanced clinical development of Valneva's Lyme disease vaccine candidate, VLA15, which is being developed in partnership with Pfizer. All vaccinations in the pivotal phase 3 trial of VLA15 have been completed, with results expected in the first half of next year. Subject to positive outcomes, Pfizer plans to seek regulatory approval in Europe and the U.S. in 2026, with a potential launch in autumn 2027. The new price target reflects increased expectations for VLA15, outweighing recent downward adjustments to forecasts for other Valneva products.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valneva SE published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_24344), on December 08, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。